All tests

Vistara Non-invasive prenatal screening test to detect monogenic fetal diseases

The Vistara test is a non-invasive prenatal test used to screen the fetus for 25 serious genetic disorders.

These disorders can cause skeletal abnormalities, heart defects, multiple congenital anomalies, and/or intellectual disability.

General characteristics of the test:

The test is performed using unique methods based on single nucleotide variants (SNVs), combined with advanced bioinformatics analysis using artificial intelligence.

— Vistara™ NIPT includes 25 of the most common autosomal dominant and X-linked dominant disorders involving 30 genes that cause severe skeletal, cardiovascular, and neurological conditions.

The monogenic disorders included in the Vistara test have the following characteristics:

  • These conditions are difficult or impossible to detect by ultrasound
  • Other NIPTs do not detect these disorders
  • Invasive testing does not guarantee an accurate diagnosis
  • Patient or family history is usually not associated with these mutations, as they typically occur de novo

Who is recommended to undergo screening for gene mutations:

  • Advanced paternal age (if the father is 40 years of age or older)
  • Pregnant women with ultrasound markers who do not wish to undergo amniocentesis
  • Individuals with a relevant family history
  • Patients who wish to obtain as much information as possible

The test is applicable:

  • In singleton pregnancies from 9 weeks of gestation
  • In pregnancies conceived using a donor egg and in surrogate pregnancies
  • In cases where the pregnant woman herself does not have a genetic disorder
  • The fetal fraction threshold used for interpretation of the test results is 4.5%

Absolute contraindications:

  • Pregnancies with more than one fetus, or pregnancies involving fetal demise, vanishing twin, or fetal reduction
  • Pregnancies with a gestational age of less than 9 weeks
  • The Vistara test is not recommended if the mother has been diagnosed with a disorder included in the test panel. If the father has been diagnosed with a disorder included in the test panel, the father’s genetic test results must be provided to Natera.

Limitations of the method:

  • Vistara is a screening test, meaning that it does not provide a definitive diagnosis. A positive Vistara screening result means that the fetus may be affected by the identified disorder. However, screening results alone cannot definitively determine whether the baby has the condition.
  • The Vistara test is limited to the disorders included in the test panel

List of conditions tested and corresponding genes:

Condition Gene
Achondroplasia (FGFR3)
Alagille syndrome (JAG1)
Antley-Bixler syndrome (FGFR2)
Apert syndrome (FGFR2)
Cardiofaciocutaneous syndrome (BRAF, MAP2K1, MAP2K2)
CATSHL syndrome (FGFR3)
CHARGE syndrome (CHD7)
Cornelia de Lange syndrome (NIPBL, SMC1A, SMC3, RAD21, HDAC8)
Costello syndrome (HRAS)
Crouzon syndrome (FGFR2, FGFR3)
Ehlers-Danlos syndrome (classical, cardiac-valvular, types VIIA and VIIB) (COL1A1, COL1A2)
Early infantile epileptic encephalopathy (CDKL5)
Hypochondroplasia (FGFR3)
Intellectual disability (SYNGAP1)
Jackson-Weiss syndrome (FGFR2)
Juvenile myelomonocytic leukemia (JMML) (PTPN11)
LEOPARD syndrome (Noonan syndrome with multiple lentigines) (PTPN11, RAF1)
Muenke syndrome (FGFR3)
Noonan syndrome (PTPN11, SOS1, RAF1, RIT1, KRAS, NRAS, SOS2, SHOC2, BRAF, MAP2K1, HRAS, CBL)
Osteogenesis imperfecta (types I, II, III, IV) (COL1A1, COL1A2)
Pfeiffer syndrome (types 1, 2, 3) (FGFR2)
Rett syndrome (MECP2)
Sotos syndrome (NSD1)
Thanatophoric dysplasia (types I, II) (FGFR3)
Tuberous sclerosis (types 1, 2) (TSC1, TSC2)

Required biological material

  • Maternal venous blood